Immune Responses to the 105AD7 Vaccine in Osteosarcoma Patients
Author Information
Author(s): Pritchard-Jones K, Spendlove I, Wilton C, Whelan J, Weeden S, Lewis I, Hale J, Douglas C, Pagonis C, Campbell B, Alvarez P, Halbert G, Durrant L G
Primary Institution: Royal Marsden Hospital and Institute of Cancer Research
Hypothesis
Can the 105AD7 vaccine induce an immune response in osteosarcoma patients who have recently completed chemotherapy?
Conclusion
The majority of young osteosarcoma patients showed measurable immune responses to the 105AD7 vaccine with no significant toxicity.
Supporting Evidence
- 71% of patients showed a significant T-cell proliferation response to the vaccine.
- 59% of patients secreted antigen-specific γIFN in response to the vaccine.
- Two patients continued vaccination for 2 years and remained disease-free.
Takeaway
This study tested a vaccine on kids with a type of bone cancer, and most of them were able to fight back against the cancer without getting sick from the vaccine.
Methodology
Patients received the 105AD7 vaccine within 1–6 months after chemotherapy, and their immune responses were measured through T-cell proliferation and γIFN secretion.
Potential Biases
Potential bias due to the small number of patients and the lack of a control group.
Limitations
The study was not designed to measure significant clinical benefit and had a small sample size.
Participant Demographics
Patients were aged under 30 years with high-grade osteosarcoma.
Statistical Information
Confidence Interval
95% CI 51–87%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website